nach oben

Cardiovascular Toxicology

Erschienen in:

27.08.2020 | Myocardial Infarction

Roles of MicroRNA-122 in Cardiovascular Fibrosis and Related Diseases

verfasst von: Ying Liu, Jia-Wei Song, Jian-Yu Lin, Ran Miao, Jiu-Chang Zhong

Erschienen in: Cardiovascular Toxicology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Fibrotic diseases cause annually more than 800,000 deaths worldwide, where of the majority accounts for cardiovascular fibrosis, which is characterized by endothelial dysfunction, myocardial stiffening and reduced dispensability. MicroRNAs (miRs), small noncoding RNAs, play critical roles in cardiovascular dysfunction and related disorders. Intriguingly, there is a critical link among miR-122, cardiovascular fibrosis, sirtuin 6 (SIRT6) and angiotensin-converting enzyme 2 (ACE2), which was recently identified as a coreceptor for SARS-CoV2 and a negative regulator of the rennin-angiotensin system. MiR-122 overexpression appears to exacerbate the angiotensin II-mediated loss of autophagy and increased inflammation, apoptosis, extracellular matrix deposition, cardiovascular fibrosis and dysfunction by modulating the SIRT6-Elabela-ACE2, LGR4-β-catenin, TGFβ-CTGF and PTEN-PI3K-Akt signaling pathways. More importantly, the inhibition of miR-122 has proautophagic, antioxidant, anti-inflammatory, anti-apoptotic and antifibrotic effects. Clinical and experimental studies clearly demonstrate that miR-122 functions as a crucial hallmark of fibrogenesis, cardiovascular injury and dysfunction. Additionally, the miR-122 level is related to the severity of hypertension, atherosclerosis, atrial fibrillation, acute myocardial infarction and heart failure, and miR-122 expression is a risk factor for these diseases. The miR-122 level has emerged as an early-warning biomarker cardiovascular fibrosis, and targeting miR-122 is a novel therapeutic approach against progression of cardiovascular dysfunction. Therefore, an increased understanding of the cardiovascular roles of miR-122 will help the development of effective interventions. This review summarizes the biogenesis of miR-122; regulatory effects and underlying mechanisms of miR-122 on cardiovascular fibrosis and related diseases; and its function as a potential specific biomarker for cardiovascular dysfunction.

Song, J. J., Yang, M., Liu, Y., Song, J. W., Wang, J., Chi, H. J., et al. (2020). MicroRNA-122 aggravates angiotensin II-mediated apoptosis and autophagy imbalance in rat aortic adventitial fibroblasts via the modulation of SIRT6-elabela-ACE2 signaling. European Journal of Pharmacology, 883, 173374. https://doi.org/10.1016/j.ejphar.2020.173374.PubMedPubMedCentralCrossRef

Ma, Z., Song, J. J., Martin, S., Yang, X. C., & Zhong, J. C. (2020). The Elabela-APJ axis: A promising therapeutic target for heart failure. Heart Failure Reviews, 27, 1–10. https://doi.org/10.1007/s10741-020-09957-5.CrossRef

Pinar, A. A., Scott, T. E., Huuskes, B. M., Tapia Cáceres, F. E., Kemp-Harper, B. K., & Samuel, C. S. (2020). Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. Pharmacology & Therapeutics, 209, 107511.

Paul, M., Amos, Z., & Wing-Kin, S. (2019). Fibrosis in chronic liver disease: An update on diagnostic and treatment modalities. Drugs, 79(9), 903–927.

Zhao, Z., Zhong, L., Li, P., He, K., Qiu, C., Zhao, L., et al. (2020). Cholesterol impairs hepatocyte lysosomal function causing M1 polarization of macrophages via exosomal miR-122-5p. Experimental Cell Research, 387(1), 111738.PubMed

Xu, R., Zhang, Z. Z., Chen, L. J., Yu, H. M., Guo, S. J., Xu, Y. L., et al. (2016). Ascending aortic adventitial remodeling and fibrosis are ameliorated with Apelin-13 in rats after TAC via suppression of the miRNA-122 and LGR4-β-catenin signaling. Peptides, 86, 85–94.PubMed

Filipowicz, W., & Grosshans, H. (2011). The liver-specific microRNA miR-122: Biology and therapeutic potential. Progress in Drug Research, 67, 221–238.PubMed

Gatfield, D., Le Martelot, G., Vejnar, C. E., Gerlach, D., Schaad, O., Fleury-Olela, F., et al. (2009). Integration of microRNA miR-122 in hepatic circadian gene expression. Genes & Development, 23(11), 1313–1326.

Rivoli, L., Vliegenthart, A. D., de Potter, C. M., van Bragt, J. J., Tzoumas, N., Gallacher, P., et al. (2017). The effect of renal dysfunction and haemodialysis on circulating liver specific miR-122. British Journal of Clinical Pharmacology, 83(3), 584–592.PubMed

10.

Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., et al. (2020). Pharmacological interventions for heart failure in people with chronic kidney disease. Cochrane Database System Review, 2(2), CD012466.

11.

Song, J. J., Ma, Z., Wang, J., Chen, L. X., & Zhong, J. C. (2020). Gender differences in hypertension. The Journal of Cardiovascular Translational Research, 13(1), 47–54.PubMed

12.

Hu, J., Wu, H., Wang, D., Yang, Z., & Dong, J. (2019). LncRNA ANRIL promotes NLRP3 inflammasome activation in uric acid nephropathy through miR-122-5p/BRCC3 axis. Biochimie, 157, 102–110.PubMed

13.

Qu, X. H., & Zhang, K. (2018). MiR-122 regulates cell apoptosis and ROS by targeting DJ-1 in renal ischemic reperfusion injury rat models. European Review for Medical and Pharmacological Sciences, 22(24), 8830–8838.PubMed

14.

Wang, Y., Liang, H., Jin, F., Yan, X., Xu, G., Hu, H., et al. (2019). Injured liver-released miRNA-122 elicits acute pulmonary inflammation via activating alveolar macrophage TLR7 signaling pathway. Proceedings of the National academy of Sciences of the United States of America, 116(13), 6162–6171.PubMedPubMedCentral

15.

Hu, Y., Du, G., Li, G., Peng, X., Zhang, Z., & Zhai, Y. (2019). The miR-122 inhibition alleviates lipid accumulation and inflammation in NAFLD cell model. Archives of Physiology and Biochemistry, 16, 1–5.

16.

Snyder-Talkington, B. N., Dong, C., Sargent, L. M., Porter, D. W., Staska, L. M., Hubbs, A. F., et al. (2016). mRNAs and miRNAs in whole blood associated with lung hyperplasia, fibrosis, and bronchiolo-alveolar adenoma and adenocarcinoma after multi-walled carbon nanotube inhalation exposure in mice. Journal of Applied Toxicology, 36(1), 161–174.PubMed

17.

Weber, G. J., Purkayastha, B., Ren, L., Pushpakumar, S., & Sen, U. (2018). Hypertension exaggerates renovascular resistance via miR-122-associated stress response in aging. Journal of Hypertension, 36(11), 2226–2236.PubMed

18.

Song, G., Zhu, L., Ruan, Z., Wang, R., & Shen, Y. (2019). MicroRNA-122 promotes cardiomyocyte hypertrophy via targeting FoxO3. Biochemical and Biophysical Research Communications, 519(4), 682–688.PubMed

19.

Zhang, H. G., Zhang, Q. J., Li, B. W., Li, L. H., Song, X. H., Xiong, C. M., et al. (2020). The circulating level of miR-122 is a potential risk factor for endothelial dysfunction in young patients with essential hypertension. Hypertension Research, 43(6), 511–517.PubMed

20.

Martínez-Micaelo, N., Beltrán-Debón, R., Baiges, I., Faiges, M., & Alegret, J. M. (2017). Specific circulating microRNA signature of bicuspid aortic valve disease. Journal of Translational Medicine, 15(1), 76.PubMedPubMedCentral

21.

Stojkovic, S., Koller, L., Sulzgruber, P., Hülsmann, M., Huber, K., Mayr, M., et al. (2020). Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure. International Journal of Cardiology, 303, 80–85.PubMed

22.

Ivey, M. J., Kuwabara, J. T., Pai, J. T., Moore, R. E., Sun, Z., & Tallquist, M. D. (2018). Resident fibroblast expansion during cardiac growth and remodeling. Journal of Molecular and Cellular Cardiology, 114, 161–174.PubMed

23.

Lin, J., & Zheng, X. (2017). Salvianolate blocks apoptosis during myocardial infarction by downregulating miR-122-5p. Current Neurovascular Research, 14(4), 323–329.PubMed

24.

Gong, L., Chang, H., & Xu, H. (2019). LncRNA MALAT1 knockdown alleviates oxygen-glucose deprivation and reperfusion induced cardiomyocyte apoptotic death by regulating miR-122. Experimental and Molecular Pathology, 111, 104325.PubMed

25.

Zhang, X., & Jing, W. (2018). Upregulation of miR-122 is associated with cardiomyocyte apoptosis in atrial fibrillation. Molecular Medicine Reports, 18(2), 1745–1751.PubMed

26.

González, A., Schelbert, E. B., Díez, J., & Butler, J. (2018). Myocardial interstitial fibrosis in heart failure: Biological and translational perspectives. Journal of the American College of Cardiology, 71(15), 1696–1706.PubMed

27.

Prabhat, R., Rajesh, K., & Kumar, V. S. (2019). Cardiac fibroblasts and cardiac fibrosis: Precise role of exosomes. Frontiers in Cell and Developmental Biology, 7, 318.

28.

Tallquist Michelle, D. (2020). Cardiac fibroblast diversity. Annual Review of Physiology, 82, 63–78.PubMed

29.

Harvey, A., Montezano, A. C., Lopes, R. A., Rios, F., & Touyz, R. M. (2016). Vascular fibrosis in aging and hypertension: Molecular mechanisms and clinical implications. Canadian Journal of Cardiology, 32(5), 659–668.PubMed

30.

Lokugamage, N., Choudhuri, S., Davies, C., Chowdhury, I. H., & Garg, N. J. (2020). Antigen-based nano-immunotherapy controls parasite persistence, inflammatory and oxidative stress, and cardiac fibrosis, the hallmarks of chronic chagas cardiomyopathy, in a mouse model of trypanosoma cruzi infection. Vaccines (Basel), 8(1), 96. https://doi.org/10.3390/vaccines8010096.CrossRef

31.

Gyöngyösi, M., Winkler, J., Ramos, I., Do, Q. T., Firat, H., McDonald, K., et al. (2017). Myocardial fibrosis: Biomedical research from bench to bedside. European Journal of Heart Failure, 19(2), 177–191.PubMedPubMedCentral

32.

Chen, L. J., Xu, R., Yu, H. M., Chang, Q., & Zhong, J. C. (2015). The ACE2/apelin signaling, microRNAs, and hypertension. International Journal of Hypertension, 2015, 896861.PubMedPubMedCentral

33.

Zhang, H. N., Xu, Q. Q., Thakur, A., Alfred, M. O., Chakraborty, M., Ghosh, A., et al. (2018). Endothe-lial dysfunction in diabetes and hypertension: Role of microRNAs and long non-coding RNAs. Life Sciences, 213, 258–268.PubMed

34.

Sygitowicz, G., Maciejak-Jastrzębska, A., & Sitkiewicz, D. (2020). MicroRNAs in the development of left ventricular remodeling and postmyocardial infarction heart failure. Polish Archives of Internal Medicine, 130(1), 59–65. https://doi.org/10.20452/pamw.15137.PubMedCrossRef

35.

Liao, C. H., Wang, C. Y., Liu, K. H., Liu, Y. Y., Wen, M. S., & Yeh, T. S. (2018). MiR-122 marks the differences between subcutaneous and visceral adiposetissuesand associates with the outcome of bariatric surgery. Obesity Research & Clinical Practice, 12(6), 570–577.

36.

Wang, Y., Jin, P., Liu, J., & Xie, X. (2019). Exosomal microRNA-122 mediates obesity-related cardiomyopathy through suppressing mitochondrial ADP-ribosylation factor-like 2. Clinical Science, 133(17), 1871–1881.PubMed

37.

Liang, W., Guo, J., Li, J., Bai, C., & Dong, Y. (2016). Downregulation of miR-122 attenuates hypoxia/ reoxygenation (H/R)-induced myocardial cell apoptosis by upregulating GATA-4. Biochemical and Biophysical Research Communications, 478(3), 1416–1422.PubMed

38.

Zhang, X., Wang, X., Wu, J., Peng, J., Deng, X., Shen, Y., et al. (2018). The diagnostic values of circulating miRNAs for hypertension and bioinformatics analysis. Bioscience Reports, 38(4), BSR20180525.PubMedPubMedCentral

39.

Gheblawi, M., Wang, K., Viveiros, A., Nguyen, O., Zhong, J., Turner, A. J., et al. (2020). Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system–celebrating the 20th Anniversary of the Discovery of ACE2. Circulation Research, 126(10), 1456–1474.PubMed

40.

Leimena, C., & Qiu, H. (2018). Non-coding RNA in the pathogenesis, progression and treatment of hypertension. International Journal of Molecular Sciences, 19(4), 927. https://doi.org/10.3390/ijms19040927.PubMedCentralCrossRef

41.

Cengiz, M., Karatas, O. F., Koparir, E., Yavuzer, S., Ali, C., Yavuzer, H., et al. (2015). Differential expression of hypertension-associated microRNAs in the plasma of patients with white coat hypertension. Medicine (Baltimore), 94(13), e693.

42.

Xu, S. (2020). Therapeutic potential of blood flow mimetic compounds in preventing endothelial dysfunction and atherosclerosis. Pharmacological Research, 155, 104737.PubMed

43.

Elhanati, S., Ben-Hamo, R., Kanfi, Y., Varvak, A., Glazz, R., Lerrer, B., et al. (2016). Reciprocal regulation between SIRT6 and miR-122 controls liver metabolism and predicts hepatocarcinoma prognosis. Cell Reports, 14(2), 234–242.PubMed

44.

Zhang, Z. Z., Cheng, Y. W., Jin, H. Y., Chang, Q., Shang, Q. H., Xu, Y. L., et al. (2017). The sirtuin 6 prevents angiotensin II-mediated myocardial fibrosis and injury by targeting AMPK-ACE2 signaling. Oncotarget, 8(42), 72302–72314.PubMedPubMedCentral

45.

Zhou, X., Wang, J., Fa, Y., & Ye, H. (2019). Signature microRNA expression profile is associated with spontaneous hypertension in African green monkey. Clinical and Experimental Hypertension, 41(3), 287–291.PubMed

46.

Menendez-Castro, C., Cordasic, N., Dambietz, T., Veelken, R., Amann, K., Hartner, A., et al. (2020). Correlations between interleukin-11 expression and hypertensive kidney injury in a rat model of renovascular hypertension. American Journal of Hypertension, 33(4), 331–340.PubMed

47.

Wang, J., Wei, L., Yang, X., & Zhong, J. (2019). Roles of growth differentiation factor 15 in atherosclerosis and coronary artery disease. Journal of the American Heart Association, 8(17), e012826.PubMedPubMedCentral

48.

Wang, Y. L., & Yu, W. (2018). Association of circulating microRNA-122 with presence and severity of atherosclerotic lesions. Peer J, 6, e5218.PubMed

49.

Li, Y., Yang, N., Dong, B., Yang, J., Kou, L., & Qin, Q. (2019). MicroRNA-122 promotes endothelial cell apoptosis by targeting XIAP: Therapeutic implication for atherosclerosis. Life Sciences, 232, 116590.PubMed

50.

Barraclough, J. Y., Joan, M., Joglekar, M. V., Hardikar, A. A., & Patel, S. (2019). MicroRNAs as prognostic markers in acute coronary syndrome patients-a systematic review. Cells, 8(12), 1572–1584.PubMedCentral

51.

Li, X. D., Yang, Y. J., Wang, L. Y., Qiao, S. B., Lu, X. F., Wu, Y. J., et al. (2017). Elevated plasma miRNA-122, -140-3p, -720, -2861, and -3149 during early period of acute coronary syndrome are derived from peripheral blood mononuclear cells. PLoS ONE, 12(9), e0184256.PubMedPubMedCentral

52.

Patel, V. B., Zhong, J. C., Grant, M. B., & Oudit, G. Y. (2016). Role of the ACE2/angiotensin 1–7 axis of the renin-angiotensin system in heart failure. Circulation Research, 118(8), 1313–1326.PubMedPubMedCentral

53.

Zhang, Z. Z., Wang, W., Jin, H. Y., McKinnie, S. M., Farhan, M., Paul, M., et al. (2017). Pyr-apelin-13 is a negative regulator of angiotensin II-mediated adverse myocardial remodeling and dysfunction. Hypertension, 70(6), 1165–1175.PubMed

54.

Koyama, S., Kuragaichi, T., Sato, Y., Kuwabara, Y., Usami, S., Horie, T., et al. (2017). Dynamic changes of serum microRNA-122-5p through therapeutic courses indicates amelioration of acute liver injury accompanied by acute cardiac decompensation. ESC Heart Failure, 4(2), 112–121.PubMed

55.

Liu, X., Meng, H., Jiang, C., Yang, S., Cui, F., & Yang, P. (2016). Differential microRNA expression and regulation in the rat model of post-infarction heart failure. PLoS ONE, 11(8), e0160920.PubMedPubMedCentral

56.

Yao, X. L., Lu, X. L., Yan, C. Y., et al. (2015). Circulating miR-122-5p as a potential novel biomarker for diagnosis of acute myocardial infarction. International Journal of Clinical and Experimental Pathology, 8(12), 16014–16019.PubMedPubMedCentral

57.

Cortez-Dias, N., Costa, M. C., Carrilho-Ferreira, P., Silva, D., Jorge, C., Calisto, C., et al. (2016). Circulating miR-122-5p/miR-133b ratio is a specific early prognostic biomarker in acute myocardial infarction. Circulation Journal, 80(10), 2183–2191.PubMed

58.

Wang, Y., Chang, W., Zhang, Y., Zhang, L., Ding, H., Qi, H., et al. (2019). Circulating miR-22-5p and miR-122-5p are promising novel biomarkers for diagnosis of acute myocardial infarction. Journal of Cellular Physiology, 234(4), 4778–4786.PubMed

59.

Fu, X., Khalil, H., Kanisicak, O., Boyer, J. G., Vagnozzi, R. J., Maliken, B. D., et al. (2018). Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. Journal of Clinical Investigation, 128(5), 2127–2143.PubMed

60.

Li, Q., Zhang, Z., Li, H., Pan, X., Chen, S., Cui, Z., et al. (2019). Lycium barbarum polysaccharides protects H9c2 cells from hypoxia-induced injury by down-regulation of miR-122. Biomedicine & Pharmacotherapy, 110, 20–28.

61.

Zhang, Z. W., Li, H., Chen, S. S., Li, Y., Cui, Z. Y., & Ma, J. (2017). MicroRNA-122 regulates caspase-8 and promotes the apoptosis of mouse cardiomyocytes. Brazilian Journal of Medical and Biological Research, 50(2), e5760.PubMedPubMedCentral

62.

Chen, C., Li, R., Ross, R. S., & Manso, A. M. (2016). Integrins and integrin-related proteins in cardiac fibrosis. Journal of Molecular and Cellular Cardiology, 93, 162–174.PubMed

63.

Zhang, Z., Li, H., Cui, Z., Zhou, Z., Chen, S., Ma, J., et al. (2019). Long non-coding RNA UCA1 relieves cardiomyocytes H9c2 injury aroused by oxygen-glucose deprivation via declining miR-122. Artificial Cells, Nanomedicine, and Biotechnology, 47(1), 3492–3499.PubMed

Titel: Roles of MicroRNA-122 in Cardiovascular Fibrosis and Related Diseases
verfasst von: Ying Liu
Jia-Wei Song
Jian-Yu Lin
Ran Miao
Jiu-Chang Zhong
Publikationsdatum: 27.08.2020
Verlag: Springer US
Schlagwörter: Myocardial Infarction
Heart Failure
Hypertension
Erschienen in: Cardiovascular Toxicology / Ausgabe 5/2020
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-020-09603-4

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Roles of MicroRNA-122 in Cardiovascular Fibrosis and Related Diseases

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

The Molecular Mechanism of Aluminum Phosphide poisoning in Cardiovascular Disease: Pathophysiology and Diagnostic Approach

The Case of Myocardial Infarction in a Fifteen-Year-Old Adolescent Caused by Toxic Substances

Correction to: The Molecular Mechanism of Aluminum Phosphide poisoning in Cardiovascular Disease: Pathophysiology and Diagnostic Approach

Role of Peroxiredoxins in Protecting Against Cardiovascular and Related Disorders

Involvement of ROS/NLRP3 Inflammasome Signaling Pathway in Doxorubicin-Induced Cardiotoxicity

TRPV4 Mediates Cardiac Fibrosis via the TGF-β1/Smad3 Signaling Pathway in Diabetic Rats